VxP Biologics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

VxP Biologics is a private, revenue-generating CDMO providing end-to-end services for biologic drug development and manufacturing. Its business model is built on a 'One Stop Shop' approach combined with niche, service-specific expertise through a network of independently operated facilities in the US, Europe, and Asia. The company targets the growing outsourcing needs of biotech and pharma companies in oncology and broader therapeutic areas, emphasizing quality, expert access, and competitive pricing to accelerate client programs from development to market.

Oncology

Technology Platform

Integrated CDMO service platform for mammalian and microbial biologics, offering process development, analytical services, formulation (parenteral/lyophilized), and cGMP clinical/commercial manufacturing.

Opportunities

The company benefits from strong tailwinds in biologics development and the biopharma industry's increasing reliance on outsourcing.

Its niche focus on complex sterile dosage forms and flexible, expert-driven model is attractive to a growing base of virtual and small biotech companies.

Risk Factors

Key risks include intense competition from larger CDMOs, operational and regulatory execution risk inherent in GMP manufacturing, and dependence on the clinical success and spending decisions of its client companies.

Competitive Landscape

VxP operates in the highly competitive biologics CDMO market, competing against large global players (e.g., Lonza, Catalent) and many smaller niche providers. Its differentiation is based on a hybrid 'One Stop Shop' model with deep, service-specific expertise and direct client access to subject matter experts.

More companies in Biologics / Biosimilars →More companies in United States →